February 8, 2012
CTI Clinical Trial and Consulting Services (CTI) announces the addition of Melanie A. Bruno, PhD, MBA as Vice President, Clinical Trial Operations. Dr. Bruno comes to CTI with over 18 years of Clinical and Regulatory drug development expertise in the biopharmaceutical and clinical research industries.
Dr. Bruno joins CTI from Kendle where she served as Vice President of Global Regulatory and Medical Affairs, Vice President of Global Regulatory, Site and Medical Affairs and Vice President of Global Regulatory and Quality for the past 9 years. In her roles, she provided oversight and management of staff in over 38 countries executing full service (Phase I-IV) and function service models in Safety/Pharmacovigilance and Medical Writing. Prior to Kendle, Dr. Bruno spent two years at Eli Lilly in US Regulatory Affairs and six years at Procter & Gamble Pharmaceuticals (P&GP) in Regulatory Affairs. While at Lilly and P&GP, Dr. Bruno provided strategic regulatory advice for development and marketed products in a wide range of therapeutic areas including gastrointestinal, psychiatric and women’s health for general, pediatric, elderly and orphan populations. Before joining industry, Dr. Bruno was a Research Scholar in the Division of Pulmonary Biology at Cincinnati Children’s Medical Center.
Dr. Bruno received her BS in Biology, PhD in Developmental & Molecular Biology and her MBA from the University of Cincinnati. She currently serves as an Adjunct Professor in the College of Pharmacy at the University of Cincinnati in the Master’s in Drug Development program.
“Dr. Bruno will be serving in a new position at CTI driven by the growth, complexity and globalization in our work that we have experienced over the past few years,” says Kevin Schwarz, Senior Vice President Clinical Trial Operations of CTI. “Dr. Bruno’s broad experience and proven success in the leadership and development of multiple clinical and regulatory research functions including: Regulatory Consulting & Submissions, Medical Affairs, Safety & Pharmacovigilance, Clinical Quality Assurance, Feasibility, Site Identification, Patient Recruitment, Clinical Trial Regulatory, Investigator Contracts, Medical Writing, Regulatory Records Management and Registries and Health Outcomes will be a great asset to CTI.”